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Abstract—C-X-C chemokines play an important role in the migration and activation
of neutrophils (PMNs) during an inflammatory event. We measured mRNA and
protein expression of the murine C-X-C chemokines macrophage inflammatory
protein-2 (MIP-2) and KC in the lungs, liver, blood, and peritoneal cavity of Swiss
Webster mice after cecal ligation and puncture (CLP). Neutralizing antibodies to
MIP-2 and KC were also used to determine the biological effects of these chemokines
on neutrophil sequestration and organ injury in the CLP model. The data showed
that early after CLP, MIP-2 mRNA and protein were expressed predominantly by
the lung, whereas KC mRNA and protein were expressed by the liver. Inhibition of
MIP-2 reduced both lung neutrophil sequestration and peritoneal neutrophil migration.
Inhibition of KC had no effect on overall neutrophil sequestration in liver but reduced
injury as measured by serum transaminases. An early survival benefit was found with
anti-KC treatment, although overall survival was not different. Our study showed a
differential expression by organs of C-X-C chemokines during sepsis and suggested
that such chemokine effects are tissue-specific.
INTRODUCTION
Abdominal sepsis remains a leading cause of morbidity and mortality among
surgical patients. Multiple organ failure or dysfunction secondary to a systemic
1Presented at the 10th Annual Meeting of the Surgical Infection Society-Europe, Istanbul, Turkey,
1997.
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inflammatory response (1, 2) is now the chief cause of mortality and morbidity.
This change can be related to current therapeutic measures that have efficiently
dealt with overwhelming infection. The neutrophil, an essential component of
the host defense mechanism (3), is also implicated in organ failure.
Understanding of the mechanisms that control neutrophil (PMN) sequestra-
tion at different anatomical sites during peritonitis could identify differences that
may be manipulated to prevent organ injury without compromising peritoneal
defense. In response to an inflammatory stimulus, rapidly streaming PMNs in
the circulation slow down (step of rolling), firmly adhere to endothelium (step
of firm adhesion), and finally migrate across the endothelium (step of transmi-
gration). Studies have shown that this multistep process depends on both PMN
and endothelial factors (4). We have previously shown (5, 6) that PMN seques-
tration or migration into different tissues after cecal ligation and puncture (CLP)
involves a differential regulation of adhesion molecules. Blockade of P-selectin
or CD 18 markedly attenuated PMN influx into the peritoneal cavity, whereas
PMN sequestration in the remote organ was unaffected. An equally important
part of PMN-endothelial interaction is the formation of PMN chemoattractants
such as C-X-C chemokines, which upregulate PMN adhesion molecules, increase
respiratory burst, and form chemical gradients. Our goal was to study the pattern
of regulation of the C-X-C chemokines in the lung and liver after CLP.
The C-X-C chemokines are peptides with a conserved cysteine residue
near the amine terminus (7). C-X-C chemokines identified in humans include
interleukin-8 (IL-8) and GRO-a/B/G (8). The protein IL-8 is not found in
rodents, and the identified C-X-C chemokines are functional homologues of
human GRO proteins. Macrophage inflammatory protein-2 (MIP-2) (9, 10),
mouse granulocyte chemotactic protein-2 (a recently described C-X-C chemo-
kine), and KC in mice are the GRO homologues (11). Murine KC was one of
the first platelet-derived growth factor-inducible competence genes to be iden-
tified and described (10). In rats, the functional homologues are the cytokine-
induced neutrophil chemotactic proteins (CINC-1, 2a, 2B, and 3) (12). Through
a heparin-binding domain, chemokines are able to bind to endothelial cell proteo-
glycans and are presented to neutrophils rolling along the endothelium (13). The
subsequent activation of the chemokine transmembrane receptor causes upreg-
ulation of CD11b/CD 18 on the neutrophil and increases respiratory burst (14).
CD11b/CD18 binds with avidity to its endothelial ligand, intercellular adhesion
molecule-1 (ICAM-1), resulting in firm endothelial adhesion that precedes trans-
endothelial migration in response to a chemical gradient. Subsequently, activated
PMNs can cause tissue injury through the release of proteases and reactive oxy-
gen species (15, 16).
There is a differential regulation of C-X-C chemokines (e.g., MIP-2 and KC
in mice) at different sites, both in constitutive expression and induction. This reg-
ulation depends on the model of injury or infection used. In a mouse model of
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viral keratitis, MIP-2 appeared to be the dominant and important chemokine, and
blockade of MIP-2 (unlike blockade of KC) reduced the incidence and severity
of keratitis (17). On the other hand, in a mouse model of Klebsiella pneumonia,
compartmentalized overexpression of KC improved survival (18). This effect,
and the fact that KC is maximally expressed earlier on in the wild-type mice,
suggested that KC was more important in the early host defense than MIP-2
in this model and was expressed much later. In a hepatic ischemia-reperfusion
model in mice, both KC and MIP-2 were shown to be important, and the block-
ade of either chemokine reduced liver injury significantly (19). In a rat model
of airway inflammation caused by fungal spores, a differential response in the
induction of the same chemokine was shown to occur with different organisms
and also concentrations of organisms (20). In this model, some organisms had
no effect on MIP-2 (or KC) expression, whereas maximal expression of MIP-2
occurred at 1 h with certain organisms and later (1–3 h) with others. We there-
fore hypothesized that after CLP in mice, MIP-2 and KC would be expressed
in the liver, lung, and peritoneal cavity, and would differentially control PMN
sequestration at these sites.
MATERIALS AND METHODS
Care of Animals. Adult male Swiss Webster mice (age 6-8 weeks, weighing 25–30 g,
Taconic, Germantown, New York) were used. Mice were housed in a facility approved by the Amer-
ican Association for Accreditation of Laboratory Animal Care and provided with food and water ad
libitum. Studies were carried out according to the National Institutes of Health guidelines and under
the supervision of a veterinarian.
Cecal Ligalion and Puncture Model. Mice were anesthetized with ketamine (80 mg/kg) and
xylazine (16 mg/kg) by intramuscular injection. CLP was performed as described previously (21).
Briefly, the cecum was exposed through a midline laparotomy incision, ligated just below the ileo-
cecal junction with 4–0 silk, and punctured twice using an 18-gauge needle. The cecum was then
returned into the peritoneal cavity, and the abdominal incision was closed with 4–0 nylon suture.
Trial Design. To investigate the expression of MIP-2 and KC, 18 mice underwent CLP. At 3,
6, and 18 h, 6 mice were sacrificed. Four mice (unmanipulated) served as normal controls. Liver and
lung were harvested for mRNA quantitation and protein expression as determined by enzyme-linked
immunosorbent assay (ELISA). Serum and peritoneal fluid protein levels were also determined by
ELISA. Mice then received intravenous anti-MIP-2 (N = 6), anti-KC (N = 6) antibody, or control
serum at the time of CLP. Six hours after CLP, mice were sacrificed. The 6 h time point was chosen
based on organ KC and MIP-2 expression as detected in the first experiment (vide infra). Liver and
lung were harvested for myeloperoxidase (MPO) quantitation, serum for transaminase levels, and
peritoneal fluid for differential leukocyte counts. Lastly, a group of mice received anti-KC antibody
(N = 18) or control serum (N = 18) at the time of CLP, and survival was determined.
Antibodies. Polyclonal anti-murine MIP-2 antibody (BioSource, Camarillo, California) was
injected at a dose of 3.3 mg/kg in 0.2 mL saline. Polyclonal rabbit anti-murine KC antibody (1:1000
titer) was injected at a dose of 150 UL of the anti-KC and 600 UL of normal saline. Control serum
was used in a similar dilution (1 part control serum to 4 parts of normal saline).
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Lung and Serum Chemokine Assays. To measure liver and lung MIP-2 and KC protein
expression, tissues from the respective organs were removed, weighed, and homogenized in a lysis
buffer containing 0.5% Triton X-100, 10 mM Tris, 0.5 mM MgCl2, 22 Ug/mL aprotinin, 100 Ug/mL
leupeptin, 1.8 mg/mL iodoacetamide, and 1 mM PMSF. Homogenates were incubated on ice for
30 min, centrifuged at 2500 rpm for 10 min, and supernatants were stored at -20°C until cytokine
levels were determined. Liver, lung, serum, and peritoneal MIP-2 levels were estimated by using
an ELISA kit (BioSource, Camarillo, California), according to the manufacturer’s instructions. KC
concentration was determined by ELISA, as previously described (22). Briefly, plates were coated
with capture antibody overnight and blocked for 1 h on the Nutator mixer (Becton Dickinson, Cock-
eyville, Maryland) before samples and standards were added. The samples and standards were also
placed on the Nutator for 1 h. Biotinylated antibody was then added for 1 h followed by streptavidin-
peroxidase (Jackson Laboratories, West Grove, Pennsylvania) for 1 h. Both reactions occurred on
the Nutator at room temperature. Peroxidase substrate was then added, and plates were allowed to
develop for 20 min in the dark before the reaction was stopped with 3M H2SO4. Plates were read
at dual wavelengths of 490 nm and 630 nm. Sample concentrations were determined by comparison
to a standard curve (both proteins from R&D Systems, Minneapolis, Minnesota). The antibody used
was a polyclonal antibody with specificity for KC.
Total Tissue RNA Extraction. Tissue extraction was performed according to the method
described by Chomczynski and Sacchi (23) using the right lung, liver tissue, and peritoneal cell
pellet.
Semi-Quantitation of MIP-2 and KC mRNA. This is a semi-quantitative competitive differ-
ential polymerase chain reaction (PCR)-based protocol described previously (24, 25). Total cellular
RNA (400 ng) was reverse-transcribed according to the Geneamp RNA PCR kit (Perkin-Elmer, Nor-
walk, Connecticut) protocol using random hexamers to prime the reverse transcriptase. For PCR of
the cDNA, the same buffer with 2.5 units of AmpliTaq DNA polymerase and a final concentration of
Mg2+ 3 mM was used. The primers for murine beta-actin (B-actin) and either KC or MIP-2 (Strata-
gene, La Jolla, California) were added in the same tube at a final concentration of 0.5 mM each. We
designed the MIP-2 primer sequences by using OLIGO software (Genbank accession number for
murine MIP-2, X53798). The KC primer sequences were obtained from a previous study described
by Oquendo, et al. (26). The primer sequences were as follows:
B-actin sense: GTGGGCCGCTCTAGGCACCA
antisense: CGGTT-GGCCTTAGGGTTCAGGGGGG (product size 245 bp)
MIP-2 sense: GAACAAAGGCAA-GGCTAACTGA
antisense: AACATAACAACATCTGGGCAAT (product size 204 bp)
KC sense: CGGAATTCGCCACCAGCCGCCTG
antisense: CGTCTAGACTTTCT-CCGTTAC-TTGG (product size 252 bp)
After a 2 min initial melting at 95°C, the mixture was amplified for 29 cycles, using a 3-
step protocol with melting at 95°C for 1 min, annealing at 59°C for 90 sec, followed by extension
at 72°C for 15 sec. The final cycle was followed by a 10-min soak at 72°C. To ensure that the
amount of cytokine cDNA was measured only during the exponential phase of the PCR amplification,
the optimum number of PCR cycles was determined for each primer pair before amplification. To
ensure that there was no amplification of contaminating genomic DNA, control samples were run
for each primer pair without the addition of reverse transcriptase. The ratios for KC to B-actin and
MIP-2 to B-actin were calculated from densitometric analysis of negative films for each individual
specimen, following electrophoresis and ethidium bromide staining of the PCR products. The size of
the fragment was confirmed with molecular weight markers. Data are presented as ratio to (3-actin.
Peritoneal Lavage. Peritoneal exudate cells were recovered in all groups by peritoneal lavage
with 4 mL of ice-cold, heparinized, RPMI 1640 medium (GIBCO/BRL, Bethesda, Maryland). For
differential leukocyte counts, cells were counted manually by hemocytometer, and cytospins were
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performed. Cells were stained with Wright's and Giemsa stain and differentially counted. Two hun-
dred cells were counted for each slide in a blinded fashion. For cell RNA extraction, total nonadher-
ent leukocytes were used and extraction performed as described above. Peritoneal MIP-2 levels were
estimated by using an ELISA kit (BioSource, Camarillo, California), according to the manufacturer's
instructions.
Serum Transaminases. Serum was assayed for aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) using colorimetric assays (Sigma Chemical Company), according to the
manufacturer's instructions. Serum transaminases are expressed as Sigma-Frankel units/mL.
Myeloperoxidase (MPO) Assay. This was performed as previously described (27). Briefly,
tissues from the right lower lung and right lobe of the liver were removed, MPO extracted, and
amounts determined spectrophotometrically.
Statistical Analysis. Survival was analyzed using Fisher's exact test and differences in
mRNA quantitation using Kruskal-Wallis test. Differences in chemokine protein levels, leukocyte
numbers, serum transaminases, and MPO levels were analyzed using ANOVA. The null hypothesis
was rejected at the P < 0.05 level.
RESULTS
MIP-2 and KC mRNA Expression. There was a differential expression of
the C-X-C chemokine mRNA depending on the anatomic site examined. In the
liver, an early increase in expression of KC mRNA was found, followed by
a later increase in expression of MIP-2 mRNA (Table 1). MIP-2 mRNA was
significantly expressed in the lung increasingly at 3 h and longer, whereas KC
mRNA was only expressed significantly at 18 h. Early after CLP, MIP-2 mRNA








































aP < 0.005 as compared to normals (Kruskal-Wallis test).
bND, not done.
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was detected in nonadherent peritoneal leukocytes, and KC mRNA was not. Only
at 6 h after CLP was there evidence of an increase in KC mRNA from peritoneal
leukocytes.
MIP-2 and KC Protein Expression. The pattern of MIP-2 and KC protein
levels after CLP in the liver and lungs was similar to their respective mRNAs
(Table 2). MIP-2 protein was found early in the lung after CLP and in increas-
ing amounts at later time points, coinciding with lung neutrophil sequestration.
Although KC protein was detected in the lung after CLP (particularly later on),
these levels were not significantly greater than control animals at any of the time
points measured. However in liver, both KC and MIP-2 protein levels were found
to be significantly high at 18 h, but the KC mRNA was expressed earlier than
MIP-2 mRNA (Table 1). Serum levels of MIP-2 were higher early on, as com-
pared with KC, which was noted to be significantly increased 18 h after CLP.
When the levels of MIP-2 in the peritoneal cavity at 6 h were compared with
serum levels at this time, there was an increasing gradient from the blood to the
peritoneal cavity.
Effect of Neutralizing Antibodies to KC and MIP-2
Peritoneal neutrophil migration: At 6 h after CLP, there was a significant
increase in the number of neutrophils in the peritoneal cavities of mice injected
with control serum compared to unmanipulated controls (Figure 1). Although
anti-KC antibodies reduced peritoneal neutrophil migration compared with con-
trol serum mice, this difference was not significant. In contrast, anti-MIP-2 anti-
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Fig. 1. Peritoneal neutrophil migration 6 h after cecal ligation and puncture (CLP) with anti-KC and
anti-MIP-2 treatment. *P < 0.05 as compared to normals (ANOVA).
body administration significantly reduced peritoneal neutrophil migration. This
time point corresponds to an increase in both MIP-2 mRNA expression (Table
1) and peritoneal exudate MIP-2 protein (Table 2).
MPO: Both liver (Figure 2) and lung MPO (Figure 3) increased signifi-
Fig. 2. Liver MPO 6 h after cecal ligation and puncture (CLP) with anti-KC and anti-MIP-2 treat-
ment.
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Fig. 3. Lung MPO 6 h after cecal ligation and puncture (CLP) with anti-KC and anti-MIP-2 treat-
ment. *P < 0.05 as compared to control (ANOVA).
cantly at 6 h after CLP as shown by serum controls when compared with normal
controls. Inhibition of MIP-2 significantly reduced lung MPO compared with
serum controls, whereas inhibition of KC had no effect. At this 6-h point, MIP-
2 protein levels in the lung were significantly elevated, but those for KC were not
(Table 2). In the liver at 6 h, KC protein levels were elevated but not significantly
(Table 2), and even though inhibition of KC reduced liver MPO, this did not
achieve statistical significance (Figure 2). Inhibition of MIP-2 had little effect
on liver MPO.
Serum transaminases: Both serum ALT and AST levels were increased
after CLP (Table 3). Inhibition of MIP-2 had no effect on either transaminase


















bP < 0.005 as compared with control IgG (ANOVA).
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Fig. 4. Survival after 18-gauge, double-puncture cecal ligation and puncture (CLP) with anti-KC
treatment. *P < 0.05 as compared to serum controls (Fisher's exact test).
level. Interestingly, inhibition of KC significantly reduced both transaminases as
compared with control.
Survival After CLP With Anti-KC Treatment. As shown in Figure 4, anti-
KC administered at the time of CLP significantly improved early, but not overall
survival.
DISCUSSION
There is evidence to suggest that the human C-X-C chemokine IL-8 plays
a pivotal role in the pathogenesis of PMN-mediated adult respiratory distress
syndrome, multiple organ failure, and death in septic patients (28, 29). The clini-
cal observations are supported by experimental work in rabbits, which produce
IL-8 similar to humans. Neutralizing antibodies to IL-8 in a rabbit endotoxemia
model inhibited lung neutrophil sequestration, improved pulmonary function,
and improved survival (30). The importance of the C-X-C chemokines in causing
organ PMN sequestration has been demonstrated by gene transfer studies. The
transfer and overexpression of MIP-2 in rat lungs and of CINC-1 in rat livers
(31, 32) resulted in local organ PMN sequestration and organ injury in the case
of CINC-1. Transgenic mice overexpressing KC in lungs have been shown to
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have significantly higher survival from pneumonia compared to wild-type mice,
as well as decreased bacterial recovery from the lung and blood. Increased PMN
influx into the lungs in these animals was also observed (18).
The current study demonstrates that KC mRNA and protein are not consti-
tutively expressed in the liver, and KC mRNA is produced early on following
CLP. This coincides with hepatic PMN sequestration, and these results are con-
sistent with those of Deutschman et al. (33), who demonstrated an early increase
in CINC mRNA in hepatocytes and Kupffer cells (and CINC protein in liver
homogenates) after CLP in rats. In a hepatic ischemia-reperfusion model in mice,
KC was induced early after injury in the liver. MIP-2 mRNA is induced later on
in this model (19). In our study, in contrast to KC, hepatic MIP-2 mRNA and
protein were constitutively expressed in small amounts, and then produced by 6
h after CLP, but protein-expression did not reach significant levels before 18 h.
A similar observation was noted by Walley et al. (34), who observed a small,
but significant increase in liver MIP-2 protein levels in CD1 mice subjected to
CLP. They also observed a much greater expression of MIP-2 protein in the lung
and peritoneum compared to the liver after CLP. The importance of KC versus
MIP-2 in the causation of liver injury is illustrated by the reduction in serum
transaminases after neutralization of KC, but not of MIP-2 after CLP. Interest-
ingly, the reduction in transaminases was achieved without an overall reduction
in liver PMN sequestration. It has been shown that transendothelial migration
rather than sinusoidal sequestration alone of primed PMNs is responsible for
hepatic parenchymal damage (35). The method we used for quantifying liver
PMN sequestration, the MPO assay, has been shown by us (5) and others to
concur with histological assessment of both sinusoidal and hepatic parenchymal
PMN sequestration. However, the liver was not flushed of blood in this study,
and it is plausible that there was an actual reduction in transendothelial migration
of PMNs in the anti-KC-treated mice.
In endotoxemic rats treated with anti-CINC antibody, a reduction in both
sinusoidal and hepatic parenchymal PMN sequestration was observed (36). How-
ever, organ injury and death in the CLP model are independent of endotoxemia,
so other mechanisms may be involved in the endotoxemia model that proba-
bly reflect the direct tissue toxicity of endotoxin or the overwhelming systemic
proinflammatory cytokine response to systemically administered endotoxin (37).
Another explanation for the reduction in liver injury is based on the observation
that the cytotoxic potential of activated PMNs depends on their adherence to
hepatocytes, and that this can be CD18-mediated (38, 39). Therefore, the atten-
uation in transmigrating PMNs may be responsible for reducing the actual he-
patic injury. C-X-C chemokines, in turn, upregulate CD 18 on PMNs (14), and
in an immune complex-induced lung injury model in rats, inhibition of CINC
reduced bronchoalveolar PMN migration as well as CD 18 expression on these
PMNs (40). In contrast, in the rat endotoxemia model mentioned above, there
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was no reduction in CD 18 on isolated hepatic PMNs after anti-CINC treatment
(36). This may indicate that the role of chemokines is differentially regulated,
depending on the animal model used. We have previously shown no reduction in
liver PMN sequestration or hepatic injury in anti-CD18-treated mice subjected
to CLP (5). In vivo and in vitro data suggest that PMN-mediated hepatic injury
is both reactive oxygen- and protease-dependent, with reactive oxygen species
potentiating protease injury (41, 42). KC has also been shown to be a potent stim-
ulator of reactive oxygen species from PMNs (14), and thus, one further expla-
nation may be that the anti-KC antibody reduced PMN cytotoxicity by blockade
of this activity. The survival data with anti-KC treatment suggest a benefit in
the early time period after CLP, although there was no significant difference in
overall survival between the two groups. Blockade of MIP-2 and KC does not
completely abrogate the hepatic injury in a murine ischemia-reperfusion model
(19). This further implies that there are other factors in the inflammatory cascade
that contribute to the injury as well.
In contrast to the expression of MIP-2 mRNA and protein observed in the
liver after CLP, both MIP-2 mRNA and protein in the lung were significantly ele-
vated at earlier time points after CLP, coinciding with lung PMN sequestration.
Also unlike in the liver, inhibition of MIP-2 reduced lung PMN sequestration.
The effect of neutralization of MIP-2 on survival was not tested since it has
already been shown that anti-MIP-2 antibody administered prior to CLP signifi-
cantly improved survival (34). This group did not measure lung PMN sequestra-
tion, and our results suggest that improvement in survival could be due to reduc-
tion in PMN-mediated lung injury. We have shown that lung injury after CLP
is, in part, PMN-mediated (2). In that study, the use of an anti-PMN antibody
reduced such lung injury. Our observations are supported by those of Schmal et
al. (43), but their model was one of direct intratracheal instillation of endotoxin
in rats. They found a time-dependent increase in MIP-2 mRNA and protein and
a similar decrease in lung MPO. In addition, they found a significant reduction in
pulmonary vascular permeability in anti-MIP-2-treated rats. As with liver sinu-
soidal PMN sequestration, PMN arrest and subsequent transendothelial migra-
tion in the lung occurs predominantly in capillaries (44). In that scenario, PMN
adhesion and migration may use different adhesion pathways than in the systemic
circulation, with physical constraints caused by lack of PMN deformability and
endothelial swelling being more relevant than selectin and (chemokine-induced)
integrin-mediated adhesion. Since lung PMN sequestration is CD18-independent
after CLP (6), the observed reduction in lung MPO in anti-MIP-2-treated mice
suggests that MIP-2 (produced predominantly by alveolar macrophages) acts
more as a chemoattractant than stimulator of adhesion molecules. This mech-
anism may not be the principal mode of action in the peritoneal cavity, since
we have shown that peritoneal PMN migration is both P-selectin- and CD18-
dependent after CLP (5, 6). Thus, MIP-2 may function as both an upregulator
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of CD18 and chemoattractant in the migration of peritoneal PMNs after CLP.
The lack of production of KC in the lung after CLP and failure to reduce PMN
sequestration after CLP with anti-KC antibody administration contrast to find-
ings of other investigators using different models of injury. Intratracheal admin-
istration of endotoxin in a rat model showed that CINC was produced within
the lung, and that its neutralization reduced lung PMN accumulation (14). In
the Klebsiella pneumonia model in mice (which also used transgenic mice with
lung-specific overexpression of KC), KC appeared to be more important than
MIP-2 in the early PMN influx in the lung (18). When CLP was performed in
endotoxin-resistant and endotoxin-sensitive mice, we found no difference in lung
KC mRNA expression, but rather a reduction in MIP-2 mRNA expression and
lung PMN accumulation in the endotoxin-resistant mice was noted (37). Thus, it
appears, that PMN migration into both liver and lung is differentially regulated,
depending on the inciting stimulus.
In early peritoneal PMN migration after CLP, MIP-2 appears to be more
important than KC. This is evident by the earlier and more significant rise in the
MIP-2 mRNA and protein levels that were noted, and the significant attenuation
of the PMN influx using anti-MIP-2 antibodies and not anti-KC antibodies. We
have shown previously (45) that this action of MIP-2 is significantly dependent
on peritoneal mast cells and also the expression of P-selectin.
These results suggest a differential modulation in the expressions and func-
tions of C-X-C chemokines, depending on the nature of the inciting stimulus,
the type of injury produced, the tissue studied, as well as the animal model used
for study. More importantly, a redundancy in the chemokine response is evident
from all of these studies. We believe the CLP model more accurately reflects
human peritonitis and organ injury and is, therefore, more relevant to the corre-
sponding human scenario of acute abdominal sepsis.
In summary, the anti-inflammatory effects of anti-KC in the liver and anti-
MIP-2 in the lung in this model of abdominal sepsis are the most effective ther-
apies we have observed. In this model, we have previously shown that neither
anti-adhesion molecule (P-, E-, L-selectins, or CD18) nor anti-cytokine (tumor
necrosis factor or IL-1) therapy have reduced organ injury or PMN sequestration.
The effects of anti-KC in reducing hepatic injury and improving early survival
without compromising peritoneal host defense deserve further study and argue
for more characterization of C-X-C chemokine function in the corresponding
human clinical scenario. The differential modulation of expression and functions
of the C-X-C chemokines in different experimental models also underscores the
importance of clinically relevant animal models to accurately translate such data
to specific human disease states.
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